Novo Nordisk A/S
 
Search
 Search

Milestones in Diabetes Care


1923  

Short-acting insulin first produced and marketed by Novo Nordisk

1932

First hospital dedicated exclusively to diabetes care established by Novo Nordisk

1946

First longer-acting insulin (NPH) developed by Novo Nordisk

1953

The first commercially available human insulin products

1973

First purified insulin developed by Novo Nordisk

1979

First purified insulin marketed in the United States by Novo Nordisk

1982

First human insulin produced and marketed by Novo Nordisk. This insulin was used as the World Health Organization standard

1985

First insulin pen delivery system – NovoPen® – designed and marketed by Novo Nordisk

1986

First premixed human insulin – 70/30 – developed and marketed by Novo Nordisk

1988

First disposable insulin pen designed and marketed by Novo Nordisk

1988

First dial-a-dose insulin delivery system introduced

1990

First comprehensive diabetes self-management training system: Novo Nordisk Diabetes Care®

1994

First disposable pen needle – NovoFine® disposable needle – designed and marketed by Novo Nordisk

1998

First meglitinide oral antidiabetic agent – Prandin® (repaglinide) tablets – introduced by Novo Nordisk

2000

Rapid-acting insulin analog – NovoLog® insulin aspart (rDNA origin) injection – approved for marketing in the United States

2001

Innovo® insulin delivery system – the first delivery device with a memory showing amount of insulin delivered and time since last dose – designed by Novo Nordisk

2001

InDuo®, the first combined blood glucose monitoring and insulin dosing system, introduced by Novo Nordisk and LifeScan, Inc.

2001

NovoLog® becomes first insulin analog approved for pump therapy

2001

Novolin® InnoLet® (human insulin [rDNA origin]) prefilled insulin doser approved for marketing in the United States

2002

NovoPen® Junior insulin delivery system, the first insulin pen with 1/2-unit increments, approved for marketing in the United States

2002

NovoLog® Mix 70/30 FlexPen®(70% insulin aspart protamine suspension and 30% insulin aspart injection, [rDNA origin]) dual-action insulin analog in a prefilled doser

2006

Levemir® (insulin detemir (rDNA origin) injection) – a long acting insulin analog – is launched


NovoFine, NovoPen, Novo Nordisk Diabetes Care, Prandin, NovoLog, Innovo, InnoLet, and FlexPen are registered trademarks of Novo Nordisk A/S. InDuo is a registered trademark of Johnson & Johnson and Novo Nordisk A/S